RxDoctor Payments Data

Barry Katz, MD

Family Medicine · Summerville, SCNPI 1942266507

Payments from drug & device makers

$7,903in general payments, 2019–2025

Across 375 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$725
  • AstraZeneca$709
  • AbbVie$707
  • Amgen$652
  • Novo Nordisk$595
  • Pfizer$549
  • plus $4K from 41 others

What the payments were for

  • Travel & lodging$4205%
  • Food & beverage$7,47795%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,903 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$186,456
Medicare patients
300
Services billed
4,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban78$75,530
OzempicSemaglutide46$68,229
RybelsusSemaglutide29$58,582
JardianceEmpagliflozin44$49,305
JanuviaSitagliptin Phosphate16$28,028
LinzessLinaclotide14$23,430
MounjaroTirzepatide19$23,211
MyrbetriqMirabegron16$17,558
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,536
JanumetSitagliptin Phos/Metformin Hcl20$14,292
Tresiba Flextouch U-200Insulin Degludec13$12,962
FarxigaDapagliflozin Propanediol12$12,099
SymbicortBudesonide/Formoterol Fumarate33$11,010
Combivent RespimatIpratropium/Albuterol Sulfate11$7,438
Spiriva RespimatTiotropium Bromide14$7,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$595$126,81175 claims
PfizerEliquis$549$75,53078 claims
Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat$192$64,14269 claims
MerckJanuvia, Janumet$29$42,32136 claims
AbbVieLinzess$707$23,43014 claims
Lilly USA, LLCMounjaro$725$23,21119 claims
AstraZenecaFarxiga, Symbicort$709$23,10945 claims
Astellas Pharma US IncMyrbetriq$85$17,55816 claims
GSKTrelegy Ellipta$212$15,53616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Summerville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →